The Melanoma and Breast Cancer Association: An Overview of their ‘Second Primary Cancers’ and the Epidemiological, Genetic and Biological correlations

Jeyakumar, Arunan; Chua, Terence C.; Lam, Alfred King‐Yin; Gopalan, Vinod

doi:10.1016/j.critrevonc.2020.102989

Cited by 13 publications

(6 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering similarities and differences between cancer types [108,109], these findings can be further exploited in the development of therapeutic agents against melanoma.…”

Section: In Silico Pharmacokinetics and Bioactivity Studymentioning

confidence: 99%

See 1 more Smart Citation

Structural and Biofunctional Insights into the Cyclo(Pro-Pro-Phe-Phe-) Scaffold from Experimental and In Silico Studies: Melanoma and Beyond

Bojarska

Breza

Remko

et al. 2022

IJMS

View full text Add to dashboard Cite

Short peptides have great potential as safe and effective anticancer drug leads. Herein, the influence of short cyclic peptides containing the Pro-Pro-Phe-Phe sequence on patient-derived melanoma cells was investigated. Cyclic peptides such as cyclo(Leu-Ile-Ile-Leu-Val-Pro-Pro-Phe-Phe-), called CLA, and cyclo(Pro-homoPro-β3homoPhe-Phe-), called P11, exert the cytotoxic and the cytostatic effects in melanoma cells, respectively. CLA was the most active peptide as it reduced the viability of melanoma cells to 50% of control at about 10 µM, whereas P11 at about 40 µM after 48 h incubation. Interestingly, a linear derivative of P11 did not induce any effect in melanoma cells confirming previous studies showing that cyclic peptides exert better biological activity compared to their linear counterparts. According to in silico predictions, cyclic tetrapeptides show a better pharmacokinetic and toxic profile to humans than CLA. Notably, the spatial structure of those peptides containing synthetic amino acids has not been explored yet. In the Cambridge Structural Database, there is only one such cyclic tetrapeptide, cyclo((R)-β2homoPhe-D-Pro-Lys-Phe-), while in the Protein Data Bank—none. Therefore, we report the first crystal structure of cyclo(Pro-Pro-β3homoPhe-Phe-), denoted as 4B8M, a close analog of P11, which is crucial for drug discovery. Comparative molecular and supramolecular analysis of both structures was performed. The DFT findings revealed that 4B8M is well interpreted in the water solution. The results of complex Hirshfeld surface investigations on the cooperativity of interatomic contacts in terms of electrostatic and energetic features are provided. In short, the enrichment ratio revealed O…H/H…O and C…H/H…C as privileged intercontacts in the crystals in relation to basic and large supramolecular H-bonding synthon patterns. Furthermore, the ability of self-assemble 4B8M leading to a nanotubular structure is also discussed.

show abstract

“…Considering similarities and differences between cancer types [108,109], these findings can be further exploited in the development of therapeutic agents against melanoma.…”

Section: In Silico Pharmacokinetics and Bioactivity Studymentioning

confidence: 99%

“…Additional data were calculated using the pkCSM platform [108]. Full toxicology profiles of analyzed compounds, including probabilities of mutagenicity, carcinogenicity, hepatotoxicity, and estrogenicity were calculated by the VenomPred web tool [106].…”

Section: In Silico Analysismentioning

confidence: 99%

Structural and Biofunctional Insights into the Cyclo(Pro-Pro-Phe-Phe-) Scaffold from Experimental and In Silico Studies: Melanoma and Beyond

Bojarska

Breza

Remko

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…15 Negative hormone receptor was correlated with increased risk of SPM, [16][17][18] which probably shared the same etiologic factors with first BC. Regarding postoperative treatment, the effect of chemotherapy remained controversial, [18][19][20] although several literatures reached the agreement that utilization of DNAdamaging chemicals led to increased incidence of SPM. 21 Radiotherapy may subject patients to a greater risk of SPM, especially lung cancer, esophageal cancer and contralateral BC.…”

Section: Introductionmentioning

confidence: 99%

Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: A Population-Based Study

Lin

et al. 2021

IJGM

View full text Add to dashboard Cite

“…It is also reported that postoperative treatment could in uence the SPM occurrence. The effect of chemotherapy remains controversial [18][19][20], although several literatures reached the agreement that utilization of DNAdamaging chemicals led to increased incidence of SPM [21]. Radiotherapy may subject patients to a greater risk for SPM, especially lung cancer, esophageal cancer and contralateral BC [22,23].…”

Section: Introductionmentioning

confidence: 99%

Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: a SEER Population-Based Analysis

Lin

Wei

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: The survival improvement in breast cancer (BC) renders the long-termsurvivorsan increasedprobability of second primary malignancy (SPM), and thus excess mortality. Although previous evidence has indicated various predictorsofSPM, little is known whether SPM incidencevaries by HER2 status of first BC. Methods: Based on BC patients registered between 2010-2018 in the NCI SEER database, we utilized standardized incidence ratio (SIR) and Poisson regression to quantify SPM occurrence compared with the general population. Then, adjusted for competing death risk, cumulative incidence function and Gray’s test were adopted to estimate the probability of SPM. Subsequent proportional subdistribution hazards regression was executedto identify the HER2 status impact on SPM risk. Finally, survival analysiswas performed.Results: A total of 409,796 first BC patients were includedand 18,283 were identified with at least one SPM. The SIR of SPM after HER2+ BC was significantly lower than HER2- BC (1.03 vs 1.13; RR, 0.92; 95% CI, 0.88-0.96; p<0.001). But the predominantly declining SPM risk was only observed for second BC (RR, 0.89; 95% CI, 0.82-0.96; p=0.003) and lung and bronchus cancer (RR, 0.84; 95% CI, 0.74-0.95; p=0.007). Further competing risk analysis verified the protective effect of HER2 positivity status on SPM occurrence.The 5-year cumulative incidence of SPM following HER2+ and HER2- BC were 5.16% and 4.09%, respectively (p<0.001). In addition, among patients suffering from SPM,HER2 positivity status contributed tobetter overall survival. Conclusion: After considering intrinsic incremental risk with age and adjusting for competing risk of death, our study demonstrated that HER2+ BC patients had lower SPM occurrence, remarkable for second BC and lung and bronchus cancer. The disparity implies the relation between SPM occurrence and therapeutic along with genetic factors underlying BC HER2 status.

show abstract

The Melanoma and Breast Cancer Association: An Overview of their ‘Second Primary Cancers’ and the Epidemiological, Genetic and Biological correlations

Cited by 13 publications

References 103 publications

Structural and Biofunctional Insights into the Cyclo(Pro-Pro-Phe-Phe-) Scaffold from Experimental and In Silico Studies: Melanoma and Beyond

Structural and Biofunctional Insights into the Cyclo(Pro-Pro-Phe-Phe-) Scaffold from Experimental and In Silico Studies: Melanoma and Beyond

Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: A Population-Based Study

Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: a SEER Population-Based Analysis

Contact Info

Product

Resources

About